Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

By : Karen A Autio, Christopher A Klebanoff, David Schaer, John Sae Wook Kauh, Susan F Slovin, Matthew Adamow, Victoria S Blinder, Manisha Brahmachary, Michelle Carlsen, Elizabeth Comen, Daniel C Danila, Thompson N Doman, Jeremy C Durack, Josef J Fox, Jill S Gluskin, David M Hoffman, Suhyun Kang, Praneet Kang, Jonathan Landa, Philomena F McAndrew, Shanu Modi, Michael J Morris, Ruslan Novosiadly, Dana E Rathkopf, Rachel Sanford, Sonya C Chapman, Courtney M Tate, Danni Yu, Phillip Wong, Heather L McArthur

DOI :

PMID :

Non disponibles.

LY3022855, CSF-1R inhibitor, CSF-1, metastatic breast cancer, metastatic castration-resistant prostate cancer

Quel kit correspond à mon application ?

Akikazu Kawase, Keigo Sekihara, Noriyuki Matsutani, Masafumi Yamaguchi, Yujin Kudo, Makoto Endo, Tetsukan Woo, Yuichi Saito, Noriyoshi Sawabata

Rosie A Harris, Elizabeth A Stokes, Tim J P Batchelor, Eveline Internullo, Doug West, Simon Jordan, Andrew G Nicholson, Ian Paul, Charlotte Jacobs, Michael Shackcloth, Sarah Feeney, Vladimir Anikin, Niall McGonigle, Richard Steyn, Maninder Kalkat, Dionisios Stavroulias, May Havinden Williams, Syed Qadri, Karen Dobbs, Vipin Zamvar, Lucy Macdonald, Surinder Kaur, Chris A Rogers, Eric Lim; VIOLET trialists

Liquid biopsy for
enhancing patient care
through reliable CTC analysis